PeerView Heart, Lung & Blood CME/CNE/CPE Video Podcast

PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.


Laura J. Zitella, MS, RN, ACNP-BC, AOCN - Taking the Fight to AML: Oncology Nurse Perspectives, Principles, and Practice in an Era of Innovative Therapies

Go online to to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, two expert nurse panelists use case-based teaching to illustrate solutions to clinical challenges associated with nursing care in the modern acute myeloid leukemia (AML) treatment landscape in which innovative therapies (including targeted agents, newer cytotoxics, and epigenetic approaches) are now core patient treatment strategies. Upon completion of this accredited CE activity, participants should be better able to: Identify the clinical signs of AML, relevant prognostic factors, and patient- or disease-related features that influence treatment selection, Discuss efficacy and safety evidence surrounding novel cytotoxic, targeted, and epigenetic therapies for AML, Develop educational strategies for patients with AML related to therapeutic expectations, adherence, safety considerations, sequential treatments, and differences among novel agent classes, Manage dosing and safety considerations for patients with AML receiving novel cytotoxic, targeted, and epigenetic therapies.


 2021-09-01  55m